Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Weber M;Weber M; Chang WL; Breier M; Ko D; Swerdlow NR
- Source:
Behavioural pharmacology [Behav Pharmacol] 2008 Dec; Vol. 19 (8), pp. 786-95.
- Publication Type:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
- Language:
English
- Additional Information
- Source:
Publisher: Lippincott Williams and Wilkins Country of Publication: England NLM ID: 9013016 Publication Model: Print Cited Medium: Internet ISSN: 1473-5849 (Electronic) Linking ISSN: 09558810 NLM ISO Abbreviation: Behav Pharmacol Subsets: MEDLINE
- Publication Information:
Publication: London : Lippincott Williams and Wilkins
Original Publication: London : Clinical Neuroscience Publishers,
- Subject Terms:
Gait Disorders, Neurologic/
*physiopathology ;
Receptors, Dopamine D2/
*physiology ;
Receptors, Dopamine D3/
*physiology ;
Sensory Gating/
*genetics;
Acoustic Stimulation/
methods ;
Analysis of Variance ;
Animals ;
Dopamine Agonists/
pharmacology ;
Dopamine Antagonists/
pharmacology ;
Dose-Response Relationship, Drug ;
Gait Disorders, Neurologic/
chemically induced ;
Gait Disorders, Neurologic/
genetics ;
Indoles/
pharmacology ;
Male ;
Neural Inhibition/
drug effects ;
Neural Inhibition/
physiology ;
Nucleus Accumbens/
drug effects ;
Piperidines/
pharmacology ;
Rats ;
Rats, Long-Evans ;
Rats, Sprague-Dawley ;
Receptors, Dopamine D2/
agonists ;
Receptors, Dopamine D3/
agonists ;
Sensory Gating/
drug effects - Abstract:
Prepulse inhibition (PPI) of the startle reflex is an operational measure of sensorimotor gating that is deficient in several brain disorders and is disrupted in rats by dopamine (DA) agonists. Robust heritable strain differences are observed between Sprague-Dawley (SD) and Long-Evans (LE) strains in sensitivity to the PPI-disruptive effects of DA agonists associated with differential gene expression in the nucleus accumbens. Here, we compared the contribution of D2 versus D3 receptors with this heritable difference, using the D3-preferential agonist (pramipexole), the mixed D3/D2 agonist (quinpirole), the mixed D1/D2-like agonist (apomorphine), and the preferential D2 antagonist (L741,626). All DA agonists disrupted PPI in SD and LE rats. Greater sensitivity for this effect was evident with apomorphine and quinpirole in SD than LE rats, but not with pramipexole. The selective D2 antagonist L741,626 preferentially reversed apomorphine-induced PPI deficits at a dose that did not alter pramipexole-induced PPI deficits. We conclude that the heritable pattern of greater PPI 'disruptability' by DA agonists in SD versus LE rats reflects differences in D2 but not D3 receptor-associated mechanisms.
- References:
Psychopharmacology (Berl). 2001 Jul;156(2-3):234-58. (PMID: 11549226)
Psychophysiology. 2005 Sep;42(5):588-94. (PMID: 16176381)
Biol Psychiatry. 1996 Jan 1;39(1):33-41. (PMID: 8719124)
J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. (PMID: 12388666)
J Pharmacol Exp Ther. 2000 Jun;293(3):1048-62. (PMID: 10869410)
Neuropsychopharmacology. 1995 Apr;12(2):139-45. (PMID: 7779242)
Am J Psychiatry. 2003 Apr;160(4):636-45. (PMID: 12668349)
CNS Neurol Disord Drug Targets. 2006 Feb;5(1):25-43. (PMID: 16613552)
Psychopharmacology (Berl). 2007 Aug;193(2):159-70. (PMID: 17393143)
Nature. 1990 Sep 13;347(6289):146-51. (PMID: 1975644)
Behav Brain Res. 2007 Aug 22;182(1):1-11. (PMID: 17570538)
Drug Discov Today. 2005 Jul 1;10(13):917-25. (PMID: 15993811)
Pharmacol Biochem Behav. 2001 Oct-Nov;70(2-3):219-26. (PMID: 11701191)
Brain Res. 2006 Nov 13;1119(1):203-14. (PMID: 16979142)
Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54. (PMID: 11549216)
Eur J Pharmacol. 1996 Sep 19;312(1):35-44. (PMID: 8891576)
Eur J Pharmacol. 1994 Oct 3;263(3):235-43. (PMID: 7843260)
J Neurochem. 2003 Nov;87(3):631-41. (PMID: 14535946)
Pharmacol Biochem Behav. 2007 May;87(1):1-10. (PMID: 17475315)
Neuropsychopharmacology. 2003 Apr;28(4):640-50. (PMID: 12655308)
Psychopharmacology (Berl). 2001 Jul;156(2-3):194-215. (PMID: 11549223)
Pharmacol Biochem Behav. 2004 Feb;77(2):291-302. (PMID: 14751457)
Psychophysiology. 1975 May;12(3):238-48. (PMID: 1153628)
J Pharmacol Exp Ther. 2004 Feb;308(2):487-94. (PMID: 14593083)
PLoS Med. 2005 Jul;2(7):e212. (PMID: 16033310)
Psychophysiology. 1978 Jul;15(4):339-43. (PMID: 693742)
Biol Psychiatry. 2008 Apr 15;63(8):748-58. (PMID: 18083141)
Schizophr Bull. 2007 Jan;33(1):69-94. (PMID: 17135482)
Psychopharmacology (Berl). 1988;94(4):507-14. (PMID: 3131796)
Behav Pharmacol. 1998 Sep;9(5-6):389-96. (PMID: 9832924)
Pharmacol Biochem Behav. 2008 Jan;88(3):306-11. (PMID: 17900675)
Eur J Pharmacol. 2000 Apr 7;394(1):47-50. (PMID: 10771033)
Neuropsychopharmacology. 1990 Jun;3(3):211-8. (PMID: 2141986)
Mol Psychiatry. 2005 Jan;10(1):40-68; image 5. (PMID: 15263907)
Psychopharmacology (Berl). 2004 Aug;174(4):452-62. (PMID: 15300359)
Biol Psychiatry. 1986 Jan;21(1):23-33. (PMID: 3080033)
Psychopharmacology (Berl). 2004 Aug;174(4):441-51. (PMID: 15300358)
Curr Pharm Des. 2003;9(8):643-71. (PMID: 12570797)
Behav Pharmacol. 1998 Sep;9(5-6):445-55. (PMID: 9832930)
Neuropsychopharmacology. 2006 Apr;31(4):721-9. (PMID: 16123742)
Am J Psychiatry. 2000 Oct;157(10):1660-8. (PMID: 11007721)
- Grant Information:
R01 MH068366 United States MH NIMH NIH HHS; R01 MH068366-04 United States MH NIMH NIH HHS; MH68366 United States MH NIMH NIH HHS
- Accession Number:
0 (Dopamine Agonists)
0 (Dopamine Antagonists)
0 (Indoles)
0 (Piperidines)
0 (Receptors, Dopamine D2)
0 (Receptors, Dopamine D3)
81226-60-0 (3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole)
- Publication Date:
Date Created: 20081121 Date Completed: 20090408 Latest Revision: 20211020
- Publication Date:
20240829
- Accession Number:
PMC3255557
- Accession Number:
10.1097/FBP.0b013e32831c3b2b
- Accession Number:
19020413
No Comments.